

R H I N O M E D

Successful Completion of Rights Issue

3 September 2024: Melbourne, Australia.

Rhinomed Limited (**Rhinomed**) is pleased to announce that that it has been successful in completing the fully underwritten 5 for 12 pro rata non-renounceable rights issue to shareholders (**Rights Issue**) announced on 23 July 2024.

118,135,035 new shares were issued to shareholders on 2 September 2024 at AUD \$0.03 per share, with 50,825,975 of those new shares issued to Mr W. Whitney George as underwriter.

The Board is very pleased with the support shown by existing shareholders through the capital raising, which has provided a total of approximately \$3.54 million (before costs) in additional working capital for Rhinomed to drive growth in the company's key markets, the USA and Australia, support Rhinomed's leading products, including Mute Snoring, Mute Mouth Tape and Rhinoswab and Rhinoswab Junior, and provide additional working capital.

Company
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global

About Rhinomed Limited

Rhinomed Limited is a Melbourne, Australia based nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.